Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Withdrawn × Colonic Neoplasms × pembrolizumab × Clear all

Phase

Status

Active not recruiting 8 Completed 5 Recruiting 4 Not yet recruiting 2 Withdrawn 1 Unknown 1 Terminated 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Carcinoma, Non-Small-Cell Lung 12 Melanoma 8 Triple Negative Breast Neoplasms 7 Breast Neoplasms 7 Squamous Cell Carcinoma of Head and Neck 6 Neoplasms 6 Multiple Myeloma 6 Head and Neck Neoplasms 6 Carcinoma, Transitional Cell 6 Pancreatic Neoplasms 5 Carcinoma, Renal Cell 5 Recurrence 3 Lung Neoplasms 3 Endometrial Neoplasms 3 Colorectal Neoplasms 3 Stomach Neoplasms 2 Sarcoma 2 Prostatic Neoplasms 2 Neoplasm Metastasis 2 Lymphoma, Large B-Cell, Diffuse 2 Lymphoma 2 Kidney Neoplasms 2 Hematologic Neoplasms 2 Glioblastoma 2 Brain Neoplasms 2 Subcutaneous panniculitis-like T-cell lymphoma 1 Spinocerebellar Degenerations 1 Sezary Syndrome 1 Sarcoma, Synovial 1 Sarcoma, Kaposi 1

Interventions

Fluorouracil 10 Leucovorin 9 Oxaliplatin 8 Bevacizumab 6 Irinotecan 5 Capecitabine 3 aflibercept 2 Exercise 2 Chemotherapy, Adjuvant 2 Cetuximab 2 Atorvastatin 2 tucatinib 1 trifluridine tipiracil drug combination 1 trastuzumab biosimilar HLX02 1 sulindac sulfone 1 sargramostim 1 retrovector encoding mutant anti-cyclin G1 1 regorafenib 1 poly ICLC 1 pidilizumab 1 pembrolizumab 1 p53 peptide 264-272, human 1 nilotinib 1 lonafarnib 1 irofulven 1 infigratinib 1 grp protein, Drosophila 1 gevokizumab 1 galactomannan 1 eicosapentaenoic acid ethyl ester 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT04231526 2024-07-31

Pembrolizumab in Early Stage Colon Cancer

University of Chicago

Phase 2 Withdrawn

Gastrointestinal

Colonic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡